Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Anionic membrane phospholipids are a class of negatively charged lipids, including phosphatidylserine (PS), phosphatidic acid, and phosphatidylinositol, that are essential components of biological membranes (Yeung et al., 2008). In healthy mammalian cells, these lipids—particularly PS—are actively maintained on the internal leaflet of the plasma membrane by ATP-dependent enzymes called flippases. However, under conditions of cellular stress, apoptosis, or malignant transformation, this asymmetry is lost, and anionic phospholipids become exposed on the external cell surface (Thorpe, 2010). This externalization serves as a critical signaling marker for phagocytosis and contributes to an immunosuppressive tumor microenvironment by inhibiting the activity of dendritic cells and T-cells (Birge et al., 2016). Consequently, anionic phospholipids have emerged as significant therapeutic targets in oncology and virology. Drugs like bavituximab are designed to bind these lipids and restore anti-tumor immune responses, while certain antibiotics like daptomycin target anionic lipids in bacterial membranes to induce depolarization and death (Huang et al., 2005). These molecules also play a central role in the pathogenesis of antiphospholipid syndrome, where autoantibodies against these lipids lead to an increased risk of vascular thrombosis.
Drugs targeting anionic membrane phospholipids typically work by binding to externalized negatively charged headgroups, such as phosphatidylserine, which are normally sequestered in the inner leaflet of healthy cells. In oncology, this binding can trigger antibody-dependent cellular cytotoxicity (ADCC) or reverse immunosuppression by blocking inhibitory signals in the tumor microenvironment. In infectious diseases, these agents may disrupt viral envelopes or bacterial membrane integrity, leading to pathogen neutralization or cell death (Thorpe, 2010; Birge et al., 2016).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Anionic membrane phospholipids.